The purpose of this study is to describe the glycemic profile of postmenopausal women treated with alpelisib plus fulvestrant using a continuous blood sugar monitoring device (FreeStyle Libre Pro) over 14 days
No linked publications found in PubMed
Inclusion Criteria: 1. Women suffering breast cancer and eligible to treatment with Alpelisib 2. Age ≥18 years 3. Menopausal women (for at least 24 months) 4. Informed Consent Form signed Exclusion Criteria: 1. Men 2. Pregnant ou child-bearing potential women